publication date: Jul. 28, 2017

Conversation with The Cancer Letter

Will Parsons: This is a fantastic opportunity to test precision oncology for pediatric patients in a large-scale way

 

Donald Will Parsons

COG study co-chair, pediatric oncologist at Baylor College of Medicine and Texas Children’s Cancer Center.

 

Though NCI-MATCH and Pediatric MATCH are similar in structure, they represent different approaches to oncology.

While a small minority of adult cancer patients in the U.S. get treated on-protocol, in pediatric oncology only a small proportion of patients receive care off-protocol. Altogether 90 percent of childhood cancer patients are treated at institutions that are part of Children’s Oncology Group.

For Pediatric MATCH, this means that any findings would be quickly transmitted through the system, making it easier to enrich cohorts of kids who may be responding to specific treatments.

Also, with this level of coordination, the standard of care could change literally overnight.

“Although pediatric cancer is a much less common disease than in adults, in one sense we do have the advantage of being able to utilize this NCI-funded clinical trial consortium, the COG, for Pediatric MATCH,” COG study co-chair Donald “Will” Parsons, a pediatric oncologist at Baylor College of Medicine and Texas Children’s Cancer Center.

“The vast majority of kids with cancer in the United States are treated at COG institutions. And so, by opening a screening protocol through COG, not just at a single site or in a small consortium, but across the entire Children’s Oncology Group, we’re really … Continue reading Will Parsons: This is a fantastic opportunity to test precision oncology for pediatric patients in a large-scale way

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.